Developing personalized therapeutics, such as VEGF-C independent lymphangio-miR-221-3p that might serve as antilymphangiogenic targets in combination with current anti-VEGF-C therapies, seems a promising direction in the treatment of early-stage CSCC patients with LN metastasis. This evidence concerns the gene VEGFC and skin squamous cell carcinoma.